CureVac presented at the 12th International mRNA Health Conference » AnlegerPlus

CureVac presented at the 12th International mRNA Health Conference

TÜBINGEN, Deutschland/BOSTON, USA – November 4, 2024 – CureVac NV (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company, is a new drug class based on Messenger-Ribonukleinsäure (mRNA) that has been developed, which is new and active data in the summer and four posts on from 12. International mRNA Health Conference will be held on 12. bis 14. November 2024 in Boston, Massachusetts, USA.

In some cases, the details of the disease, treatment and immunization dose escalation data from the phase 1 study on the cure of CVGBM treatment in patients with reseziertem glioblastomagestellt were presented in more detail. First data from this study would provide a follow-up to the conference of the European Society for Medical Oncology (ESMO). If you consider that treatment with a CVGBM monotherapy is erolgreich Krebsantigen-specific T-Zell-Antworten for 77% of induced patients, for 84% of immunity the new one by the Impfstoff erzeugden. Data from the dose escalations study of the study has appeared on the results of the 39. Annual Report of the Society for Immunotherapy of Cancer (SITC) which has been released in the final phase of statistics.

In a few weeks, a CureVacs solution is optimized for the LNP system. The poster, which appeared at the conference, has described a number of further data from the optimization of the CureVacs mRNA platform and a new biological image for such research programs. The data that has developed the potential of the mRNA platform for healing technology in technology optimization, oncology and infectious diseases will bring major innovation in the mRNA field.

“If the young newcomers develop a new generation and promote the development of the future and the innovation of the development of mRNA medicines in different potencies, the healing is better, the boundaries of the mRNA are becoming better and better. There have been many reports about the clinical data from our Glioblastoma mRNA implementation program, which is based on our successful research into lipid nanoparticle technology, oncology and infection prevention,” says Dr. Myriam Mendila, Chief Scientific Officer at Cure Vacuum. “These presentations demonstrate our long-standing commitment, patient mRNA technology across a broad spectrum, and a high level of arousal.”

Details in the past:

Title: Development of multi-epitope mRNA vaccines – first results from phase I human trial in glioblastoma patients
Session type: Mundlich presentation
Date: Donnerstag, November 14
Hours: 1:44 PM, EST
Speaker: Regina Heidenreich, Ph.D., senior director of oncology preclinical development, CureVac SE

Title: Development and optimization of lipid nanoparticles for the delivery of mRNA vaccines
Session type: Mundlich presentation
Date: Donnerstag, November 14
Hours: 9:38 AM, EST
Speaker: Paula Muresan, Ph.D., Research Scientist, CureVac SE

More information about conference and the program can be posted on the website: https://www.mrna-conference.com/

Uber CureVac

CureVac (Nasdaq: CVAC) is a retired multinational biotech company that grew into the war in 2000, a technology of bone RNA (mRNA) for the Anwendung in human medicine. Over the years of the Entwicklung, optimization and recovery lungs, the most biological molecular substances for Mediterranean sweat that CureVac grundlegende Schlüsseltechnologien eingeführt and refinement were, which are unique for the production of mRNA-Impfstoffen against COVID-19, and those of the Grundstein before that time used mRNA in new therapeutic areas with an uncovered decay. CureVac has developed mRNA technology in combination with advanced omics and computerized work, standardizing and personalizing credit candidates for the enterprise and the connection. If you turn on the external program for prophylactic impffstoffe and treatment, the human body is produced in the low fresh, your own and therapeutic protein. CureVac operates in Hauptsitz in Tübingen, Germany, and stops in Standorte in the Lower Countries, Belgium, Switzerland and the USA. More information can be found at www.curevac.com.

CureVac Media and Investor Relations Contact

Dr. Sarah Fakih, Vice President of Corporate Communications and Investor Relations
CureVac, Tubingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
[email protected]

Zukunftsgerichtete Aussagen von CureVac

This press conference created the US Private Securities Litigation Reform Act of 1995, including the US, US, US Private Securities Litigation Reform Act of 1995 and Tochtergesellschaften CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands BV (nachfolgend “das Unternehmen”) have an overview of the first years or the 1990s of the last century. Beispiele herefür is de Erörterung der potenziellen Wirksamkeit der Impfstoff- und Behandlingskankern der Unternehmens und der Stratingen der Unternehmens, de Finanzierungspläne, Cash Runways Erwartungen, de Wachstumsmöglichkeiten und des Marktwachstums. In an own Fällen können Sie solche zkunftsgerichteten Aussagen en Begriffen wie “antizipieren”, “beabsichtigen”, “glauben”, “schätzen”, “planen”, “anstreben”, “projizieren”, “erwarten”, “können”, “werden ” , “würden”, “könnten”, “potential”, “beabsichtigen” or “sollten”, dem neglige dieser Begriffe or ähnlichen Ausdrücken recognise. Zukunftgericht Aussagen basieren on de active Einschätzungen and Annahmen des Managements anyway auf Informationen, die dem Unternehmen derzeit zur Verfügung stehen. These targeted outsourcings have no guarantee for the Leistung des Unternehmens, and they will never come out of the blue again. It may happen that there are risks, other problems and variable values, a negative prosperous clause that counteracts instability and volatility in the world markets, the financial markets, the financial markets elle and zukünftige präclinical studies and clinical studies during the timetable, the Costs and the Uncertainty of the Management of Zulassung, the Abhängigkeit of Dritten and Kooperationspartnersn, der Fähigkeit, Produkte zu vermarkten, der Fähigkeit, Produkte herzustellen, mögliche Änderungen der actuellen und planted Gesetze, Regulations and Regierungspolitik, Druck durch zunehmenden und Konsolidierung in der Branche des Unternehmens, de Auswirkungen der COVID-19 pandemic op de Geschäft und de Betriebsergebnisse des Unternehmens, de Fähigkeit, das Wachstum zu bewältigen, de Abhängigkeit von Schlüsselpersonal, de Abhängigkeit vom Schutz des geistigen Eigentums, de Fähigkeit, für die Sicherheit of the patients will be taken care of , Schwankungen der Betriebsergebnisse aufgrund der Auswirkungen von Wechselkursen, or other Factors. Solche Risiken und Ungewissheiten can take flight, while the Aussagen is a new sin, and the Leser were warned, they would have a solution for the Solche Aussagen to verlass. If you lie about the control of the internal networks and the implementation of the control, the very skill of the non-distinguishing entities does not matter. The press conferences aimed at the press have now appeared at the time of the publication of the documents. If you perform a simple view, and it is possible to perform an extension or a wider view of the revision, you can view a simple or wider mirror, which is created for written.

For more information about the message and the document of the Unternehmens, which is a fact in addition to the US Securities and Exchange Commission (der “SEC”). You can find this document on EDGAR on the SEC’s website at www.sec.gov.